- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 164219, 8 pages
Protection of Trigonelline on Experimental Diabetic Peripheral Neuropathy
Base for Drug Clinical Trial, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
Received 17 July 2012; Accepted 4 November 2012
Academic Editor: Bashar Saad
Copyright © 2012 Ji-Yin Zhou and Shi-Wen Zhou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. S. Pinzur, “Diabetic Peripheral Neuropathy,” Foot and Ankle Clinics, vol. 16, no. 2, pp. 345–349, 2011.
- A. J. M. Boulton, A. I. Vinik, J. C. Arezzo et al., “Diabetic neuropathies: a statement by the American Diabetes Association,” Diabetes Care, vol. 28, no. 4, pp. 956–962, 2005.
- A. A. Habib and T. H. Brannagan III, “Therapeutic strategies for diabetic neuropathy,” Current Neurology and Neuroscience Reports, vol. 10, no. 2, pp. 92–100, 2010.
- C. L. Chang and C. S. Lin, “Phytochemical composition, antioxidant activity, and neuroprotective effect of terminalia chebula retzius extracts,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 125247, 7 pages, 2012.
- Y. F. Xian, Z. X. Lin, Q. Q. Mao, et al., “Bioassay-guided isolation of neuroprotective compounds from Uncaria rhynchophylla against beta-amyloid-induced neurotoxicity,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 802625, 8 pages, 2012.
- J. Zhou, L. Chan, and S. Zhou, “Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease,” Current Medicinal Chemistry, vol. 19, no. 21, pp. 3523–3531, 2012.
- T. Zia, S. N. Hasnain, and S. K. Hasan, “Evaluation of the oral hypoglycaemic effect of Trigonella foenum-graecum L. (methi) in normal mice,” Journal of Ethnopharmacology, vol. 75, no. 2-3, pp. 191–195, 2001.
- S. Thakran, M. R. Siddiqui, and N. Z. Baquer, “Trigonella foenum graecum seed powder protects against histopathological abnormalities in tissues of diabetic rats,” Molecular and Cellular Biochemistry, vol. 266, no. 1-2, pp. 151–159, 2004.
- R. Moorthy, K. Prabhu, and P. Murthy, “Studies on the isolation and effect of orally active hypoglycemic principle from the seeds of fenugreek (Trigonella foenum graecum),” Diabetes Bulletin, vol. 9, pp. 69–72, 1989.
- J. Mishkinsky, B. Joseph, and F. G. Sulman, “Hypoglycaemic effect of trigonelline,” The Lancet, vol. 2, no. 7529, pp. 1311–1312, 1967.
- O. Yoshinari and K. Igarashi, “Anti-diabetic effect of trigonelline and nicotinic acid, on KK-Ay mice,” Current Medicinal Chemistry, vol. 17, no. 20, pp. 2196–2202, 2010.
- O. Yoshinari, H. Sato, and K. Igarashi, “Anti-diabetic effects of pumpkin and its components, trigonelline and nicotinic acid, on goto-kakizaki rats,” Bioscience, Biotechnology and Biochemistry, vol. 73, no. 5, pp. 1033–1041, 2009.
- A. E. Van Dijk, M. R. Olthof, J. C. Meeuse, E. Seebus, R. J. Heine, and R. M. Van Dam, “Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance,” Diabetes Care, vol. 32, no. 6, pp. 1023–1025, 2009.
- M. R. Olthof, A. E. Van Dijk, C. F. Deacon, R. J. Heine, and R. M. Van Dam, “Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones,” Nutrition and Metabolism, vol. 8, article 10, 2011.
- T. Bakuradze, R. Lang, T. Hofmann et al., “Antioxidant effectiveness of coffee extracts and selected constituents in cell-free systems and human colon cell lines,” Molecular Nutrition and Food Research, vol. 54, no. 12, pp. 1734–1743, 2010.
- W. J. Yen, B. S. Wang, L. W. Chang, and P. D. Duh, “Antioxidant properties of roasted coffee residues,” Journal of Agricultural and Food Chemistry, vol. 53, no. 7, pp. 2658–2663, 2005.
- J. Zhou, S. Zhou, and S. Zeng, “Experimental diabetes treated with trigonelline: effect on beta cell and pancreatic oxidative parameters,” Fundamental & Clinical Pharmacology. In press.
- J. Y. Zhou, S. W. Zhou, S. Y. Zeng, J. Y. Zhou, M. J. Jiang, and Y. He, “Hypoglycemic and hypolipidemic effects of ethanolic extract of mirabilis jalapa L. Root on normal and diabetic mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 257374, 9 pages, 2012.
- A. Harkavyi and P. S. Whitton, “Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection,” British Journal of Pharmacology, vol. 159, no. 3, pp. 495–501, 2010.
- T. Perry, H. W. Holloway, A. Weerasuriya et al., “Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy,” Experimental Neurology, vol. 203, no. 2, pp. 293–301, 2007.
- T. Himeno, H. Kamiya, K. Naruse, et al., “Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice,” Diabetes, vol. 60, no. 9, pp. 2397–2406, 2011.
- R. Bianchi, I. Cervellini, C. Porretta-Serapiglia, et al., “Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy,” The Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 1, pp. 64–72, 2012.
- W. J. Liu, H. Y. Jin, K. A. Lee, S. H. Xie, H. S. Baek, and T. S. Park, “Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats,” British Journal of Pharmacology, vol. 164, no. 5, pp. 1410–1420, 2011.
- H. Y. Jin, W. J. Liu, J. H. Park, H. S. Baek, and T. S. Park, “Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats,” Archives of Medical Research, vol. 40, no. 7, pp. 536–544, 2009.
- Y. Li, T. Perry, M. S. Kindy et al., “GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 4, pp. 1285–1290, 2009.
- C. G. Jolivalt, M. Fineman, C. F. Deacon, R. D. Carr, and N. A. Calcutt, “GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice,” Diabetes, Obesity & Metabolism, vol. 13, no. 11, pp. 990–1000, 2011.
- S. Agthong and D. R. Tomlinson, “Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy,” Annals of the New York Academy of Sciences, vol. 973, pp. 359–362, 2002.
- S. X. Jin, Z. Y. Zhuang, C. J. Woolf, and R. R. Ji, “p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain,” Journal of Neuroscience, vol. 23, no. 10, pp. 4017–4022, 2003.
- J. Y. Zhou, S. W. Zhou, K. B. Zhang et al., “Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats,” Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1169–1176, 2008.
- C. Courteix, A. Eschalier, and J. Lavarenne, “Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain,” Pain, vol. 53, no. 1, pp. 81–88, 1993.
- K. A. Sullivan, J. M. Hayes, T. D. Wiggin et al., “Mouse models of diabetic neuropathy,” Neurobiology of Disease, vol. 28, no. 3, pp. 276–285, 2007.
- A. M. Vincent, J. W. Russell, K. A. Sullivan et al., “SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy,” Experimental Neurology, vol. 208, no. 2, pp. 216–227, 2007.
- L. J. Coppey, J. S. Gellett, E. P. Davidson, J. A. Dunlap, D. D. Lund, and M. A. Yorek, “Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve,” Diabetes, vol. 50, no. 8, pp. 1927–1937, 2001.
- A. Guven, O. Yavuz, M. Cam, C. Comunoglu, and O. Sevinc, “Central nervous system complications of diabetes in streptozotocin-induced diabetic rats: a histopathological and immunohistochemical examination,” International Journal of Neuroscience, vol. 119, no. 8, pp. 1155–1169, 2009.
- K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
- M. H. Kedees, M. Grigoryan, Y. Guz, and G. Teitelman, “Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia,” Molecular and Cellular Endocrinology, vol. 311, no. 1-2, pp. 69–76, 2009.
- J. Zhou and S. Zhou, “Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes,” European Journal of Pharmacology, vol. 649, no. 1–3, pp. 390–397, 2010.
- P. Kakkar, B. Das, and P. N. Viswanathan, “A modified spectrophotometric assay of superoxide dismutase,” Indian Journal of Biochemistry and Biophysics, vol. 21, no. 2, pp. 130–132, 1984.
- H. H. Draper and M. Hadley, “Malondialdehyde determination as index of lipid peroxidation,” Methods in Enzymology, vol. 186, pp. 421–431, 1990.
- V. Carozzi, A. Chiorazzi, A. Canta et al., “Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity,” European Journal of Cancer, vol. 45, no. 4, pp. 656–665, 2009.
- A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman, “Oxidative stress in the pathogenesis of diabetic neuropathy,” Endocrine Reviews, vol. 25, no. 4, pp. 612–628, 2004.
- R. Bianchi, B. Buyukakilli, M. Brines et al., “Erythropoietin both protects from and reverses experimental diabetic neuropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 823–828, 2004.
- A. M. Vincent, L. M. Hinder, R. Pop-Busui, and E. L. Feldman, “Hyperlipidemia: a new therapeutic target for diabetic neuropathy,” Journal of the Peripheral Nervous System, vol. 14, no. 4, pp. 257–267, 2009.
- F. A. White, H. Jung, and R. J. Miller, “Chemokines and the pathophysiology of neuropathic pain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 51, pp. 20151–20158, 2007.
- T. Purves, A. Middlemas, S. Agthong et al., “A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy,” FASEB Journal, vol. 15, no. 13, pp. 2508–2514, 2001.
- T. A. Temraz, W. E. Houssen, M. Jaspars et al., “A pyridinium derivative from Red Sea soft corals inhibited voltage-activated potassium conductances and increased excitability of rat cultured sensory neurones,” BMC Pharmacology, vol. 6, no. 10, pp. 1–19, 2006.
- C. Tohda, N. Nakamura, K. Komatsu, and M. Hattori, “Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells,” Biological and Pharmaceutical Bulletin, vol. 22, no. 7, pp. 679–682, 1999.
- C. Tohda, T. Kuboyama, and K. Komatsu, “Search for natural products related to regeneration of the neuronal network,” NeuroSignals, vol. 14, no. 1-2, pp. 34–45, 2005.
- A. K. Saini, A. Kumar, and S. S. Sharma, “Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy,” European Journal of Pharmacology, vol. 568, no. 1–3, pp. 164–172, 2007.
- A. Kumar, R. K. Kaundal, S. Iyer, and S. S. Sharma, “Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy,” Life Sciences, vol. 80, no. 13, pp. 1236–1244, 2007.
- A. E. Valsecchi, S. Franchi, A. E. Panerai, P. Sacerdote, A. E. Trovato, and M. Colleoni, “Genistein, a natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: anti-inflammatory and antioxidant activity,” Journal of Neurochemistry, vol. 107, no. 1, pp. 230–240, 2008.
- R. Stavniichuk, V. R. Drel, H. Shevalye et al., “Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation,” Experimental Neurology, vol. 230, no. 1, pp. 106–113, 2011.